[1]
|
Vogelmeier, C.F., Criner, G.J., Martinez, F.J., Anzueto, A., Barnes, P.J., Bourbeau, J., et al. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Sum-mary. Archivos de Bronconeumología, 53, 128-149. https://doi.org/10.1016/j.arbres.2017.02.001
|
[2]
|
Kardos, P., Wencker, M., Glaab, T., et al. (2007) Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 175, 144-149. https://doi.org/10.1164/rccm.200602-244OC
|
[3]
|
Ernst, P., Gonzalez, A.V., Brassard, P. and Suissa, S. (2007) Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and the Risk of Hospitalization for Pneu-monia. American Journal of Respiratory and Critical Care Medicine, 176, 162-166. https://doi.org/10.1164/rccm.200611-1630OC
|
[4]
|
Suissa, S., Kezouh, A. and Ernst, P. (2010) Inhaled Cortico-steroids and the Risks of Diabetes Onset and Progression. The American Journal of Medicine, 123, 1001-1006. https://doi.org/10.1016/j.amjmed.2010.06.019
|
[5]
|
Crim, C., Calverley, P.M., Anderson, J.A., et al. (2009) Pneumonia Risk in COPD Patients Receiving Inhaled Corticosteroids Alone or in Combination: TORCH Study Results. European Respiratory Journal, 34, 641-647.
https://doi.org/10.1183/09031936.00193908
|
[6]
|
李正欢, 张晓云, 陈杨, 等. 2020年慢性阻塞性肺疾病全球倡议《COPD诊断、治疗与预防全球策略》指南解读(一)——稳定期药物管理[J]. 中国全科医学, 2021, 24(8): 923-929.
|
[7]
|
Martinez, F.J., Fabbri, L.M., Ferguson, G.T., et al. (2017) Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. Chest, 152, 1169-1178. https://doi.org/10.1016/j.chest.2017.07.007
|
[8]
|
Karner, C., Chong, J. and Poole, P. (2014) Tiotropium versus Placebo for Chronic Obstructive Pulmonary Disease. Cochrane Database of Systematic Reviews, 7, CD009285. https://doi.org/10.1002/14651858.CD009285.pub3
|
[9]
|
Ray, R., Tombs, L., Naya, I., et al. (2019) Efficacy and Safety of the Dual Bronchodilator Combination Umeclidinium/Vilanterol in COPD by Age and Airflow Limitation Se-verity: A Pooled Post Hoc Analysis of Seven Clinical Trials. Pulmonary Pharmacology and Therapeutics, 57, Article ID: 101802. https://doi.org/10.1016/j.pupt.2019.101802
|
[10]
|
Calverley, P.M.A., Anzueto, A.R., Carter, K., et al. (2018) Tiotropium and Olodaterol in the Prevention of Chronic Obstructive Pulmonary Disease Exacerbations (DYNAGITO): A Double-Blind, Randomised, Parallel-Group, Active-Controlled Trial. The Lancet Respiratory Medi-cine, 6, 337-344. https://doi.org/10.1016/S2213-2600(18)30102-4
|
[11]
|
Rabe, K.F., Calverley, P.M.A., Martinez, F.J., et al. (2017) Effect of Roflumilast in Patients with Severe COPD and a History of Hospitalisation. European Res-piratory Journal, 50, Article ID: 1700158.
https://doi.org/10.1183/13993003.00158-2017
|
[12]
|
中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版) [J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
|
[13]
|
Pascoe, S., Barnes, N., Brusselle, G., et al. (2019) Blood Eosinophils and Treatment Response with Triple and Dual Combination Therapy in Chronic Obstructive Pulmonary Disease: Analysis of the IMPACT Trial. The Lancet Respiratory Medicine, 7, 745-756. https://doi.org/10.1016/S2213-2600(19)30190-0
|
[14]
|
Miravitlles, M., Tonia, T., Rigau, D., et al. (2018) New Era for European Respiratory Society Clinical Practice Guidelines: Joining Efficiency and High Methodological Standards. European Respiratory Journal, 51, Article ID: 1800221.
https://doi.org/10.1183/13993003.00221-2018
|
[15]
|
Martinez, F.J., Calverley, P.M., Goehring, U.M., et al. (2015) Effect of Roflumilast on Exacerbations in Patients with Severe Chronic Obstructive Pulmonary Disease Uncontrolled by Combination Therapy (REACT): A Multicentre Randomized Controlled Trial. The Lancet, 385, 857-866. https://doi.org/10.1016/S0140-6736(14)62410-7
|
[16]
|
Martinez, F.J., Rabe, K.F., Sethi, S., et al. (2016) Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2- Agonist on Chronic Obstructive Pulmonary Disease Exacerba-tions (RE2SPOND). A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 194, 559-567. https://doi.org/10.1164/rccm.201607-1349OC
|
[17]
|
Han, M.K., Tayob, N., Murray, S., et al. (2014) Pre-dictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy. American Journal of Respiratory and Critical Care Medicine, 189, 1503-1508. https://doi.org/10.1164/rccm.201402-0207OC
|
[18]
|
Albert, R.K., Connett, J., Bailey, W.C., et al. (2011) Azithro-mycin for Prevention of Exacerbations of COPD. The New England Journal of Medicine, 365, 689-698.
|
[19]
|
Lee, S.H., Lee, J.H., Yoon, H.I., et al. (2019) Change in Inhaled Corticosteroid Treatment and COPD Exacerbations: An Analysis of Real-World Data from the KOLD/KOCOSS Cohorts. Respiratory Research, 20, Article No. 62.
|
[20]
|
Chapman, K.R., Hurst, J.R., Frent, S.M., et al. (2018) Long-Term Triple Therapy De-Escalation to Indacaterol/Glyco- pyrronium in Pa-tients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple- Dummy Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 198, 329-339.
https://doi.org/10.1164/rccm.201803-0405OC
|
[21]
|
Rossi, A., Guerriero, M., Corrado, A. and Group, O.A.S. (2014) Withdrawal of Inhaled Corticosteroids Can Be Safe in COPD Patients at Low Risk of Exacerbation: A Real-Life Study on the Appropriateness of Treatment in Moderate COPD Patients (OPTIMO). Respiratory Research, 15, Article No. 77. https://doi.org/10.1186/1465-9921-15-77
|
[22]
|
Vogelmeier, C., Worth, H., Buhl, R., et al. (2017) “Re-al-Life” Inhaled Corticosteroid Withdrawal in COPD: A Subgroup Analysis of DACCORD. International Journal of Chronic Obstructive Pulmonary Disease, 12, 487-494.
https://doi.org/10.2147/COPD.S125616
|
[23]
|
Wouters, E.F., Postma, D.S., Fokkens, B., et al. (2005) Withdrawal of Fluticasone Propionate from Combined Salmeterol/Fluticasone Treatment in Patients with COPD Causes Immediate and Sustained Disease Deterioration: A Randomised Controlled Trial. Thorax, 60, 480-487. https://doi.org/10.1136/thx.2004.034280
|
[24]
|
Rossi, A., van der Molen, T., del Olmo, R., et al. (2014) INSTEAD: A Randomised Switch Trial of Indacaterol versus Salmeterol/Fluticasone in Moderate COPD. European Respiratory Journal, 44, 1548-1556.
|
[25]
|
Magnussen, H., Disse, B., Rodriguez-Roisin, R., et al. (2014) Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. The New England Journal of Medicine, 371, 1285-1294. https://doi.org/10.1056/NEJMoa1407154
|
[26]
|
Calzetta, L., Matera, M.G., Braido, F., et al. (2017) Withdrawal of Inhaled Corticosteroids in COPD: A Meta-Analysis. Pulmonary Pharmacology & Therapeutics, 45, 148-158. https://doi.org/10.1016/j.pupt.2017.06.002
|
[27]
|
Papi, A., Vestbo, J., Fabbri, L., et al. (2018) Extrafine Inhaled Tri-ple Therapy versus Dual Bronchodilator Therapy in Chronic Obstructive Pulmonary Disease (TRIBUTE): A Dou-ble-Blind, Parallel Group, Randomised Controlled Trial. The Lancet, 391, 1076-1084. https://doi.org/10.1016/S0140-6736(18)30206-X
|
[28]
|
Suissa, S., Coulombe, J. and Ernst, P. (2015) Discontinua-tion of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia. Chest, 148, 1177-1183. https://doi.org/10.1378/chest.15-0627
|
[29]
|
Wedzicha, J.A., Calverley, P.M., Seemungal, T.A., et al. (2008) The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide. American Journal of Respiratory and Critical Care Medicine, 177, 19-26. https://doi.org/10.1164/rccm.200707-973OC
|
[30]
|
Anzueto, A., Ferguson, G.T., Feldman, G., et al. (2009) Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes. COPD: Jour-nal of Chronic Obstructive Pulmonary Disease, 6, 320-329.
https://doi.org/10.1080/15412550903140881
|
[31]
|
Rennard, S.I., Tashkin, D.P., Mcelhattan, J., et al. (2009) Effi-cacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metereddose Inhaler in Patients with Chronic Obstructive Pulmonary Disease: Results from a 1-Year Randomized Controlled Clinical Trial. Drugs, 69, 549-565.
https://doi.org/10.2165/00003495-200969050-00004
|
[32]
|
Tashkin, D.P., Rennard, S.I., Martin, P., et al. (2008) Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease: Results of a 6-Month Randomized Clinical Trial. Drugs, 68, 1975-2000.
https://doi.org/10.2165/00003495-200868140-00004
|
[33]
|
Welte, T., Miravitlles, M., Hernandez, P., et al. (2009) Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmo-nary Disease. American Journal of Respiratory and Critical Care Medicine, 180, 741-750. https://doi.org/10.1164/rccm.200904-0492OC
|
[34]
|
Kew, K.M. and Seniukovich, A. (2014) Inhaled Steroids and Risk of Pneumonia for Chronic Obstructive Pulmonary Disease. Cochrane Database of Systematic Reviews, 3, CD010115. https://doi.org/10.1002/14651858.CD010115.pub2
|
[35]
|
Sin, D.D., Tashkin, D., Zhang, X., et al. (2009) Budesonide and the Risk of Pneumonia: A Meta-Analysis of Individual Patient Data. The Lancet, 374, 712-719. https://doi.org/10.1016/S0140-6736(09)61250-2
|
[36]
|
Vestbo, J., Papi, A., Corradi, M., et al. (2017) Single Inhaler Extrafine Triple Therapy versus Long-Acting Muscarinic Antagonist Therapy for Chronic Obstructive Pulmonary Dis-ease (TRINITY): A Double-Blind, Parallel Group, Randomised Controlled Trial. The Lancet, 389, 1919-1929. https://doi.org/10.1016/S0140-6736(17)30188-5
|
[37]
|
Suissa, S., Patenaude, V., Lapi, F. and Ernst, P. (2013) In-haled Corticosteroids in COPD and the Risk of Serious Pneumonia. Thorax, 68, 1029-1036. https://doi.org/10.1136/thoraxjnl-2012-202872
|
[38]
|
Garcha, D.S., Thurston, S.J., Patel, A.R., et al. (2012) Changes in Prevalence and Load of Airway Bacteria Using Quantitative PCR in Stable and Exacerbated COPD. Thorax, 67, 1075-1080.
https://doi.org/10.1136/thoraxjnl-2012-201924
|
[39]
|
Brassard, P., Suissa, S., Kezouh, A. and Ernst, P. (2011) In-haled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases. American Journal of Respiratory and Critical Care Medicine, 183, 675-678.
https://doi.org/10.1164/rccm.201007-1099OC
|
[40]
|
Sonnappa, S., Martin, R., Israel, E., et al. (2017) Risk of Pneumonia in Obstructive Lung Disease: A Real-Life Study Comparing Extra-Fine and Fine-Particle Inhaled Corticoster-oids. PLOS ONE, 12, e0178112.
https://doi.org/10.1371/journal.pone.0178112
|
[41]
|
Oshagbemi, O.A., Franssen, F.M.E., van Kraaij, S., et al. (2019) Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD). COPD: Journal of Chronic Obstructive Pulmonary Disease, 16, 152-159. https://doi.org/10.1080/15412555.2019.1608172
|
[42]
|
Halpin, D., Criner, G.J., Papi, A., et al. (2021) Global Initi-ative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 203, 24-36.
https://doi.org/10.1164/rccm.202009-3533SO
|
[43]
|
Oshagbemi, O.A., Odiba, J.O., Daniel, A., et al. (2019) Abso-lute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy among Patients with COPD: Systematic Review and Meta-Analysis. Current Drug Targets, 20, 1670- 1679. https://doi.org/10.2174/1389450120666190808141625
|
[44]
|
Scichilone, N., Basile, M., Battaglia, S., et al. (2014) What Proportion of Chronic Obstructive Pulmonary Disease Outpatients Is Eligible for Inclusion in Randomized Clinical Trials? Respiration, 87, 11-17.
https://doi.org/10.1159/000355082
|
[45]
|
Schermer, T.R., Hendriks, A.J., Chavannes, N.H., et al. (2004) Probabil-ity and Determinants of Relapse after Discontinuation of Inhaled Corticosteroids in Patients with COPD Treated in Gen-eral Practice. Primary Care Respiratory Journal, 13, 48-55. https://doi.org/10.1016/j.pcrj.2003.11.005
|
[46]
|
Nadeem, N.J., Taylor, S.J. and Eldridge, S.M. (2011) Withdrawal of Inhaled Corticosteroids in Individuals with COPD—A Systematic Review and Comment on Trial Methodology. Res-piratory Research, 12, Article No. 107.
https://doi.org/10.1186/1465-9921-12-107
|
[47]
|
Pavord, I.D., Lettis, S., Locantore, N., Pascoe, S., Jones, P.W., Wedzicha, J.A., et al. (2016) Blood Eosinophils and Inhaled Corticosteroid/Long-Acting Beta-2 Agonist Efficacy in COPD. Thorax, 71, 118-125.
https://doi.org/10.1136/thoraxjnl-2015-207021
|
[48]
|
Hastie, A.T., Martinez, F.J., Curtis, J.L., Doerschuk, C.M., Hansel, N.N., Christenson, S., et al. (2017) Association of Sputum and Blood Eosinophil Concentrations with Clinical Measures of COPD Severity: An Analysis of the SPIROMICS Cohort. The Lancet Respiratory Medicine, 5, 956-967. https://doi.org/10.1016/S2213-2600(17)30432-0
|
[49]
|
Couillard, S., Larivee, P., Courteau, J. and Vanasse, A. (2017) Eosinophils in COPD Exacerbations Are Associated with Increased Readmissions. Chest, 151, 366-373. https://doi.org/10.1016/j.chest.2016.10.003
|
[50]
|
Suissa, S., Dell’Aniello, S. and Ernst, P. (2018) Comparative Ef-fectiveness of LABA-ICS versus LAMA as Initial Treatment in COPD Targeted by Blood Eosinophils: Apopula-tion-Based Cohort Study. The Lancet Respiratory Medicine, 6, 855-862. https://doi.org/10.1016/S2213-2600(18)30368-0
|
[51]
|
Siva, R., Green, R.H., Brightling, C.E., et al. (2007) Eosin-ophilic Airway Inflammation and Exacerbations of COPD: A Randomised Controlled Trial. European Respiratory Journal, 29, 906-913.
https://doi.org/10.1183/09031936.00146306
|
[52]
|
Zysman, M., Deslee, G., Caillaud, D., et al. (2017) Relationship between Blood Eosinophils, Clinical Characteristics, and Mortality in Patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease, 12, 1819- 1824. https://doi.org/10.2147/COPD.S129787
|
[53]
|
Casanova, C., Celli, B.R., de-Torres, J.P., et al. (2017) Prevalence of Persistent Blood Eosinophilia: Relation to Outcomes in Pa-tients with COPD. European Respiratory Journal, 50, Article ID: 1701162.
https://doi.org/10.1183/13993003.01162-2017
|
[54]
|
Bafadhel, M., McKenna, S., Terry, S., et al. (2012) Blood Eo-sinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Placebo-Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 186, 48-55. https://doi.org/10.1164/rccm.201108-1553OC
|
[55]
|
Turato, G., Semenzato, U., Bazzan, E., et al. (2018) Blood Eo-sinophilia Neither Reflects Tissue Eosinophils Nor Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Dis-ease. American Journal of Respiratory and Critical Care Medicine, 197, 1216-1219. https://doi.org/10.1164/rccm.201708-1684LE
|
[56]
|
Harlander, M., Barrecheguren, M., Turel, M. and Miravitlles, M. (2017) Should Patients Switched from D to B in the GOLD 2017 Classification Be Discontinued from Inhaled Cor-ticosteroids? COPD: Journal of Chronic Obstructive Pulmonary Disease, 14, 465-468. https://doi.org/10.1080/15412555.2017.1342233
|
[57]
|
Rogliani, P., Ritondo, B.L., Gabriele, M., Cazzola, M. and Calzetta, L. (2020) Optimizing De-Escalation of Inhaled Corticosteroids in COPD: A Systematic Review of Real-World Findings. Expert Review of Clinical Pharmacology, 13, 977-990. https://doi.org/10.1080/17512433.2020.1817739
|